Compare VVOS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | ENVB |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 8.1M |
| IPO Year | 2020 | 2000 |
| Metric | VVOS | ENVB |
|---|---|---|
| Price | $0.43 | $1.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 487.8K | 132.7K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $17,443,000.00 | ★ $39,914,675.00 |
| Revenue This Year | $69.66 | N/A |
| Revenue Next Year | $48.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $0.38 | $0.56 |
| 52 Week High | $7.40 | $13.25 |
| Indicator | VVOS | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 36.40 |
| Support Level | $0.38 | $0.60 |
| Resistance Level | $0.55 | $1.58 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 31.76 | 35.19 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.